Arcticzymes Technologies ASA
Research Arcticzymes Technologies ASA (B4V) on Bullrun: valuation model: 57.2% overvalued, market cap EUR 88.10M, P/E 86.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerB4V
- ExchangeF
- CountryNorway
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Valuation signal57.2% overvalued
- Market capEUR 88.10M
- P/E86.3
- Financial periodFY2024
- RevenueNOK 104.35M
- Revenue growth-12.3%
- Net incomeNOK 8.47M
- Free cash flowNOK 726.00K
Valuation Snapshot
Bullrun's latest valuation model marks Arcticzymes Technologies ASA as 57.2% overvalued; latest market cap is EUR 88.10M; P/E is 86.3.
About Arcticzymes Technologies ASA
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents;
Frequently asked questions
Is Arcticzymes Technologies ASA overvalued or undervalued?
Bullrun's valuation model currently marks Arcticzymes Technologies ASA as 57.2% overvalued.
What is Arcticzymes Technologies ASA's market cap?
Arcticzymes Technologies ASA's market capitalization is EUR 88.10M.
What is Arcticzymes Technologies ASA's P/E ratio?
Arcticzymes Technologies ASA's price-to-earnings (P/E) ratio is 86.3.
What does Arcticzymes Technologies ASA do?
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase;